Journals / Klinik Psikofarmakoloji Bülteni / 2005 / Cilt: 15 - Sayı: 2

Pharmacological management of pervasive developmental disorders

Yaygın gelişimsel bozukluklarda ilaç seçimi

Pages
53–59
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Children who have these symptoms and comorbid medical conditions with PDD should be evaluated throughly for drug treatment in clinical practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to determine the predictors of psychotropic medication use in children with pervasive developmental disorders (PDD) by evaluating the differences between children under treatment and or not.
📊
Key Findings & Data:Method: Two hundred and fifty six children with PDD who were referred to Ankara University School of Medicine, Department of Child and Adolescent Psychiatry Clinic between 2000-2002 were reviewed retrospectively.
💡
Conclusion & Impact:Children who have these symptoms and comorbid medical conditions with PDD should be evaluated throughly for drug treatment in clinical practice.
🔬Design:Review & Systematic Survey
📍Scope:2000-2002 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to determine the predictors of psychotropic medication use in children with pervasive developmental disorders (PDD) by evaluating the differences between children under treatment and or not. Method: Two hundred and fifty six children with PDD who were referred to Ankara University School of Medicine, Department of Child and Adolescent Psychiatry Clinic between 2000-2002 were reviewed retrospectively. Sociodemographic data, PDD symptoms of children, drugs, and comarbidity were obtained by a semi-structured form. Results: Psychotropic medication was used in the 37.5% (n=96) of the patients. Atypical antipsychotics were the most preferred drugs. Hyperactivity, attention deficit, self-mutilation, eating problem, and perseveration symptoms were detected as significant predictors for drug usage. In addition, the rates of children with comorbid medical disorder, EEG abnormality and past seizure history were significantly higher in the medication using group. Conclusion: Behavioral problems were the most important factor in drug use. Children who have these symptoms and comorbid medical conditions with PDD should be evaluated throughly for drug treatment in clinical practice.

Özet

Amaç: Bu çalışmada Yaygın Gelişimsel Bozukluğu(YGB) olan çocuklarda, ilaç alan ve almayan olgular arasındaki farklılıklar değerlendirilerek YGB olan olgularda ilaç kullanımını yordayan faktörlerin belirlenmesi amaçlanmıştır. Yöntem: Çalışmada Ankara Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Kliniği'ne 2000-2002 yılları arasında başvuruda bulunan ve herhangi bir YGB tanısı alan 256 çocuğa ait bilgiler geriye dönük olarak değerlendirilmiştir. Sosyodemografik veriler, çocuklarda bulunan YGB belirtileri, kullanılan ilaçlar, eşlik eden tıbbi ve psikiyatrik durumlarla ilgili veriler yarı yapılandırılmış bir görüşme ile elde edilmiştir. Bulgular: Olguların %37.5'inde (n=96) psikiyatrik belirtiler nedeniyle ilaç tedavisi kullanıldığı görülürken, %62.5'inde (n=160) ilaç kullanılmamıştır. En çok tercih edilen ilaçların atipik antipsikotikler olduğu görülmüştür. Hiperaktivite, dikkat eksikliği, kendine zarar verici davranış, yeme sorunu ve perseverasyon belirtilerinin ilaç kullanımının yordayıcıları olduğu bulunmuştur. Ek olarak ilaç kullanan grupta eşlik eden tıbbi hastalığı, EEG anormalliği ve nöbet geçirme öyküsü olan çocukların oranı anlamlı olarak daha fazla bulunmuştur. Sonuç: YGB olan olgularda ilaç kullanımında daha çok davranış bozukluklarının belirleyici olduğu görülmüştür. Sözü geçen belirtilere sahip olan ve eşlik eden tıbbi hastalığı bulunan YGB olan çocuklar ilaç kullanımı açısından daha dikkatli ele alınmalıdır.

🔖

Cite This Article

AKÇAKIN, M., AYSEV, S. A., GÜRKAN, K. (2022). Pharmacological management of pervasive developmental disorders. Klinik Psikofarmakoloji Bülteni, Cilt: 15 - Sayı: 2, 53–59. https://ajindex.com/articles/574446

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. American Psychiatric Association(APA). Diagnostic and statistical manual of mental disorders(DSM-IV). Washington DC, American Psychiatric Association, 1994 2. Hollander E, Philips AT, Yeh C. Targeted treatments for symptom domains in child and adolescent autism. The Lancet 2003
  2. 734 3. Campbell M, Schopler E, Cueva JE, Hallin A. Treatment of autistic disorder. J Am Acad Child Adolesc Psychiatry 1996
  3. 143 4. Campbell M, Rapoport JL, Simpson GM. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999
  4. 545 5. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symtoms in autistic children. J Autism Dev Disord 1989
  5. 239 6. Perry R, Campbell M, Adams P et al. Long term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989
  6. 92 7. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg RP, Overall JR. Neuroleptic related dyskinesias in autistic children: A prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 1997
  7. 843 8. Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999
  8. 174 9. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001
  9. 1214 10. Stavrakaki C, Antochi R, Emery PC. Olanzapine in the treatment of pervasive developmental disorders: A case series analysis. J Psychiatry Neurosci 2004
  10. 60 11. McDougle CJ, Kem DL, Posey DJ. Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002
  11. 927 12. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002
  12. 147 13. Diler RS, Firat S, Avc› A. An open-label trial of risperidone in children with autism. Curr Ther Res Clin Exp 2002
  13. 102 14. Mukaddes NM, Abalı O, Gurkan K. Short-term efficacy and safety of risperidone in young children with autistic disorder(AD). World J Biol Psychiatry 2004
  14. 214 15. Miral S, Gencer Ö, Emiroğlu N, Baykara B, Baykara A, Dirik E. Otistik bozuklukta risperidon ve haloperidolün etkinlik ve güvenli